96 related articles for article (PubMed ID: 3939276)
21. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
22. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients.
Miyata M; Shirakawa T; Acharya B; Terao S; Gotoh A
ASAIO J; 2006; 52(3):272-5. PubMed ID: 16760715
[TBL] [Abstract][Full Text] [Related]
23. [Use of prostaglandins in extracorporeal circulation and hemodialysis].
Zaorska B
Pol Tyg Lek; 1981 Jun; 36(23):857-60. PubMed ID: 7024949
[No Abstract] [Full Text] [Related]
24. Application of a prostacyclin analogue (PG) and protease inhibitor (FUT) as anticoagulants with an LVAD system.
Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Furuse A; Asano K; Yoshitake T; Kazama M
ASAIO Trans; 1986; 32(1):253-7. PubMed ID: 3535842
[No Abstract] [Full Text] [Related]
25. Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits.
Annich G; White T; Damm D; Zhao Y; Mahdi F; Meinhardt J; Rebello S; Lucchesi B; Bartlett RH; Schmaier AH
Thromb Haemost; 1999 Nov; 82(5):1474-81. PubMed ID: 10595641
[TBL] [Abstract][Full Text] [Related]
26. Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy.
Palevsky PM; Burr R; Moreland L; Tokiwa Y; Greenberg A
ASAIO J; 1995; 41(4):847-9. PubMed ID: 8589465
[TBL] [Abstract][Full Text] [Related]
27. Activation of coagulation during hemodialysis: effect of blood lines alone and whole extracorporeal circuit.
Lucchi L; Ligabue G; Marietta M; Delnevo A; Malagoli M; Perrone S; Stipo L; Grandi F; Albertazzi A
Artif Organs; 2006 Feb; 30(2):106-10. PubMed ID: 16433843
[TBL] [Abstract][Full Text] [Related]
28. [Biocompatibility and extracorporeal circulation].
Camici M
Clin Ter; 1995 Nov; 146(11):713-9. PubMed ID: 8720347
[TBL] [Abstract][Full Text] [Related]
29. Platelet factor release following heparin administration and during extracorporeal circulation.
Flicker W; Milthorpe BK; Schindhelm K; Odell RA; McPherson J; Farrell PC
Trans Am Soc Artif Intern Organs; 1982; 28():431-6. PubMed ID: 6219490
[No Abstract] [Full Text] [Related]
30. [Clinical study of prostacyclin in extracorporeal circulation. Effects on hemodynamics and coagulation].
Fabiani JN; Bunting S; Terrier E; O'Grady J; Fontaine B; Prigent C; Carpentier A; Vane J; Dubost C
Arch Mal Coeur Vaiss; 1982 Mar; 75(3):241-8. PubMed ID: 6807240
[TBL] [Abstract][Full Text] [Related]
31. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation.
Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M
Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775
[TBL] [Abstract][Full Text] [Related]
32. Regional citrate anticoagulation in chronic hemodialysis patients.
Seaton RD; Duncan KA; Pinnick RV; Diederich DA; Wiegmann TB
Trans Am Soc Artif Intern Organs; 1983; 29():414-8. PubMed ID: 6673262
[TBL] [Abstract][Full Text] [Related]
33. [Use of a thromboxane synthetase inhibitor for the protection of platelet number and function during extracorporeal circulation. Experimental study].
Massonnet Castel S; Pelissier E; Fabiani JN; Terrier E
Agressologie; 1983 Dec; 24(12):605-8. PubMed ID: 6686919
[No Abstract] [Full Text] [Related]
34. Failure of a protease inhibitor to affect the cardiopulmonary response to endotoxin when combined with a cyclooxygenase inhibitor.
Traber DL; Adams T; Sziebert L; Williams P; Traber LD
Circ Shock; 1984; 13(4):319-23. PubMed ID: 6434194
[TBL] [Abstract][Full Text] [Related]
35. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass.
Muriithi EW; Belcher PR; Rao JN; Chaudhry MA; Nicol D; Wheatley DJ
J Thorac Cardiovasc Surg; 2000 Sep; 120(3):538-43. PubMed ID: 10962416
[TBL] [Abstract][Full Text] [Related]
36. New surface treatments to prevent thrombosis during extracorporeal circulation.
Splittgerber FH; Whittlesey GC; Klein MD
Trans Am Soc Artif Intern Organs; 1985; 31():474-8. PubMed ID: 3837492
[No Abstract] [Full Text] [Related]
37. Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation.
Addonizio VP; Fisher CA; Bowen JC; Palatianos GC; Colman RW; Edmunds LH
Trans Am Soc Artif Intern Organs; 1981; 27():304-7. PubMed ID: 7036500
[TBL] [Abstract][Full Text] [Related]
38. Effects of prolonged heparinless venoarterial bypass on blood coagulation in sheep.
Wakabayaski A; Woolley TO; Nakamura Y; Connolly JE
Surg Forum; 1975; 26():250-2. PubMed ID: 1216128
[No Abstract] [Full Text] [Related]
39. Citrate anticoagulation control by ionized calcium levels does not prevent hemostasis and complement activation during hemodialysis.
Opatrný K; Richtrová P; Polanská K; Wirth J; Sefrna F; Brandl M; Falkenhagen D
Artif Organs; 2007 Mar; 31(3):200-7. PubMed ID: 17343695
[TBL] [Abstract][Full Text] [Related]
40. [Premises to the study of blood coagulation changes in the course of extracorporeal circulation].
Respighi E; Marcazzan E; Panzeri E
Arch Chir Torac Cardiovasc; 1968; 25(3):207-27. PubMed ID: 4910329
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
